At LogiPharma USA 2026, supply chain leaders gathered to examine where artificial intelligence delivers genuine value across pharmaceutical distribution networks.
PAXAFE’s Mark Talens took to the stage to deliver a clear message: foundational visibility must be established before AI can generate meaningful results in supply chain operations.
Talens argued that many organisations are rushing toward advanced AI implementation without first solving more fundamental data and visibility challenges that undermine any intelligent system built on top of them.
His central point was that shared distribution visibility, when properly implemented, creates the contextual foundation that AI systems require to produce reliable and actionable outcomes.
Without that shared context across distribution partners, AI tools risk drawing conclusions from incomplete or siloed data, producing recommendations that can mislead rather than improve operations.
The pharmaceutical sector faces particular challenges in this regard, given the complexity of its cold chain requirements, regulatory obligations, and the high stakes involved in product integrity.
Talens suggested that the clearest supply chain wins from AI are not coming from sophisticated predictive models but from applying intelligent tools to the basics of operational visibility and data sharing.
Organisations that have invested in getting visibility fundamentals right are seeing stronger returns from their AI deployments compared to those that have skipped that groundwork entirely.
The LogiPharma USA 2026 conference served as a forum for practitioners across the pharmaceutical supply chain to share lessons learned and identify where technology investment is genuinely paying off.
Talens’ remarks reflect a growing consensus among supply chain professionals that AI is most effective when it augments clear, well-structured operational data rather than attempting to compensate for its absence.
The conversation around AI in pharma logistics is maturing, with leaders increasingly focused on implementation discipline and data quality rather than the promise of the technology alone.
For companies seeking competitive advantage in pharmaceutical distribution, the message from LogiPharma USA 2026 appears consistent: build the visibility infrastructure first, then layer intelligence on top of it.